Chronic urticaria treatment
Pro Research Analysisby 
Searched over 200M research papers
Chronic Urticaria Treatment: First-Line and Stepwise Approaches
Second-generation H1 antihistamines are the first-line treatment for chronic urticaria due to their safety and effectiveness. If symptoms persist, the dose can be increased up to four times the standard recommendation, although this is considered off-label use. If there is still no improvement, omalizumab, an anti-IgE monoclonal antibody, is recommended as the next step. For patients who do not respond to omalizumab, cyclosporine can be added to the treatment regimen. Short-term systemic corticosteroids may be used for acute flare-ups or in refractory cases, but are not recommended for long-term management due to side effects 2356+2 MORE.
Biologic Therapies and Emerging Treatments for Chronic Urticaria
Omalizumab has significantly improved outcomes for patients with antihistamine-resistant chronic urticaria, especially chronic spontaneous urticaria (CSU). Newer anti-IgE biologics, such as ligelizumab and UB-221, are in clinical trials and show promise, with ligelizumab demonstrating even greater efficacy in some studies. Other biologics under investigation include dupilumab, reslizumab, mepolizumab, and benralizumab, which target different immune pathways involved in urticaria. Additional novel therapies in development include Bruton’s tyrosine kinase inhibitors (e.g., remibrutinib, fenebrutinib), spleen tyrosine kinase inhibitors, and monoclonal antibodies targeting Siglec-8 and other mast cell receptors 1458.
Adjunctive and Combination Therapies
For patients with comorbidities or those who do not respond to standard treatments, combination therapies are sometimes used. These may include adding H2 antihistamines, leukotriene receptor antagonists (such as montelukast), dapsone, or hydroxychloroquine. These combinations have been shown to be feasible and generally safe, even in patients with multiple comorbidities 39.
Special Populations: Older Adults and Children
Treatment recommendations for older adults and children generally follow the same stepwise approach as for the general population, starting with second-generation antihistamines and progressing to omalizumab and cyclosporine if needed. However, in older adults, careful drug selection is important due to the higher likelihood of comorbidities and polypharmacy, which can complicate management 110.
Personalized and Future Approaches in Chronic Urticaria Management
There is growing recognition that chronic urticaria is a heterogeneous disease with different underlying mechanisms. Personalized, endotype-based approaches are emerging, focusing on identifying specific drivers such as autoantibodies. New targeted therapies, including anti-cytokine drugs and mast cell-depleting agents, are being developed to address these individual differences and unmet needs in treatment 158.
Conclusion
Chronic urticaria treatment typically begins with second-generation antihistamines, escalating to higher doses and then to omalizumab if needed. For refractory cases, cyclosporine and other adjunctive therapies may be considered. New biologics and targeted therapies are in development, offering hope for more effective and personalized management in the future. The choice of therapy should be tailored to the individual, especially in special populations such as older adults and those with comorbidities.
Sources and full results
Most relevant research papers on this topic
New treatments for chronic urticaria.
New treatments for chronic urticaria, including off-label use of existing drugs and novel therapies in clinical trials, show promise in improving patient outcomes.
DOI